MERIDIAN BIOSCIENCE INC (VIVO)
US5895841014 - Common Stock
Overall VIVO gets a fundamental rating of 6 out of 10. We evaluated VIVO against 188 industry peers in the Health Care Equipment & Supplies industry. VIVO scores excellent points on both the profitability and health parts. This is a solid base for a good stock. VIVO is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
VIVO had positive earnings in the past year.
VIVO had a positive operating cash flow in the past year.
Each year in the past 5 years VIVO has been profitable.
Each year in the past 5 years VIVO had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 9.17%, VIVO belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
The Return On Equity of VIVO (11.54%) is better than 87.50% of its industry peers.
Looking at the Return On Invested Capital, with a value of 14.66%, VIVO belongs to the top of the industry, outperforming 94.44% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for VIVO is significantly above the industry average of 8.23%.
The 3 year average ROIC (49.65%) for VIVO is well above the current ROIC(14.66%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.17% | ||
| ROE | 11.54% | ||
| ROIC | 14.66% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)49.65%
ROIC(5y)N/A
1.3 Margins
VIVO has a Profit Margin of 12.75%. This is amongst the best in the industry. VIVO outperforms 87.04% of its industry peers.
In the last couple of years the Profit Margin of VIVO has grown nicely.
VIVO has a Operating Margin of 22.70%. This is amongst the best in the industry. VIVO outperforms 93.52% of its industry peers.
In the last couple of years the Operating Margin of VIVO has remained more or less at the same level.
VIVO's Gross Margin of 56.56% is in line compared to the rest of the industry. VIVO outperforms 55.56% of its industry peers.
VIVO's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.7% | ||
| PM (TTM) | 12.75% | ||
| GM | 56.56% |
OM growth 3Y5.46%
OM growth 5Y0.35%
PM growth 3Y1.65%
PM growth 5Y3.46%
GM growth 3Y-1.43%
GM growth 5Y-1.79%
2. Health
2.1 Basic Checks
VIVO has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
VIVO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VIVO has more shares outstanding
Compared to 1 year ago, VIVO has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 11.77 indicates that VIVO is not in any danger for bankruptcy at the moment.
VIVO has a Altman-Z score of 11.77. This is amongst the best in the industry. VIVO outperforms 88.89% of its industry peers.
VIVO has a debt to FCF ratio of 0.34. This is a very positive value and a sign of high solvency as it would only need 0.34 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.34, VIVO belongs to the top of the industry, outperforming 93.52% of the companies in the same industry.
VIVO has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
VIVO has a Debt to Equity ratio of 0.07. This is comparable to the rest of the industry: VIVO outperforms 56.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.34 | ||
| Altman-Z | 11.77 |
ROIC/WACC1.53
WACC9.57%
2.3 Liquidity
VIVO has a Current Ratio of 3.63. This indicates that VIVO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.63, VIVO is in line with its industry, outperforming 50.00% of the companies in the same industry.
VIVO has a Quick Ratio of 2.46. This indicates that VIVO is financially healthy and has no problem in meeting its short term obligations.
VIVO has a Quick ratio of 2.46. This is comparable to the rest of the industry: VIVO outperforms 45.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.63 | ||
| Quick Ratio | 2.46 |
3. Growth
3.1 Past
VIVO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.86%.
The Earnings Per Share has been growing by 15.21% on average over the past years. This is quite good.
VIVO shows a small growth in Revenue. In the last year, the Revenue has grown by 4.76%.
The Revenue has been growing by 10.65% on average over the past years. This is quite good.
EPS 1Y (TTM)-17.86%
EPS 3Y26.61%
EPS 5Y15.21%
EPS Q2Q%-12.5%
Revenue 1Y (TTM)4.76%
Revenue growth 3Y18.33%
Revenue growth 5Y10.65%
Sales Q2Q%-13.82%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-39.02%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-13.66%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 24.62 indicates a rather expensive valuation of VIVO.
Compared to the rest of the industry, the Price/Earnings ratio of VIVO indicates a rather cheap valuation: VIVO is cheaper than 83.80% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 29.20, VIVO is valued at the same level.
With a Price/Forward Earnings ratio of 40.37, VIVO can be considered very expensive at the moment.
VIVO's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. VIVO is cheaper than 75.93% of the companies in the same industry.
VIVO's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.62 | ||
| Fwd PE | 40.37 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, VIVO is valued cheaper than 86.57% of the companies in the same industry.
VIVO's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VIVO is cheaper than 94.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.27 | ||
| EV/EBITDA | 15.62 |
4.3 Compensation for Growth
The excellent profitability rating of VIVO may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.62
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
VIVO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MERIDIAN BIOSCIENCE INC
NASDAQ:VIVO (1/30/2023, 8:27:46 PM)
After market: 33.99 +0.02 (+0.06%)33.97
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.49B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.62 | ||
| Fwd PE | 40.37 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)1.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.17% | ||
| ROE | 11.54% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 22.7% | ||
| PM (TTM) | 12.75% | ||
| GM | 56.56% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.63 | ||
| Quick Ratio | 2.46 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-17.86%
EPS 3Y26.61%
EPS 5Y
EPS Q2Q%
EPS Next Y-39.02%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)4.76%
Revenue growth 3Y18.33%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y